en · de · es · fr · pt
assay-notes.peptides3626.com › Wiki › Molecular Background And Immune Action — Beginner to Advanced

Molecular Background And Immune Action — Beginner to Advanced

By Editorial Desk · published 2025-10-22 · last reviewed 2025-11-11 · Wiki

A practical reference on thymosin alpha 1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-11-11. Anything still debated is marked as such rather than presented as settled.

Molecular Background and Immune Action

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Molecular Identity Of Thymosin Alpha-1

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular mass≈3,108 DaSynthetic 28-residue peptide
Amino acid count28N-terminal serine carries an acetyl group
AppearanceWhite to off-white powderLyophilized solid
Water solubilityFreely solubleDissolves in aqueous buffer
Common synonymsThymalfasin; Tα1Thymalfasin is the international nonproprietary name

Background and Molecular Profile

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Related pages on this site

Research History and Clinical Assessment

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Further detail

In the 1950s the neurotransmitter dopamine was discovered in the brain by Katharine Montagu, and characterised as a neurotransmitter a year later by Arvid Carlsson, for which he would be awarded the Nobel Prize. A. N. Ernst then discovered in 1965 that apomorphine was a powerful stimulant of dopamine receptors. This, along with the use of sublingual apomorphine tablets, led to a renewed interest in the use of apomorphine as a treatment for alcoholism. A series of studies of non-emetic apomorphine in the treatment of alcoholism were published, with mostly positive results. However, there was little clinical consequence.

=== Sugar manufacturing === Ion-exchange resins are used in the manufacturing of sugar from various sources. They are used to help convert one type of sugar into another type of sugar (e.g. glucose isomerization resins convert glucose to fructose under mild conditions, enabling high-fructose syrup production) and to decolorize and purify sugar syrups. This is due to the strong-acid cation resins which exchange metal and color impurities, producing the desired clear, and light-colored sugar syrup.

chromatography Any of a variety of laboratory methods designed to separate a heterogeneous mixture into its component chemical species by first dissolving the mixture in a gas or liquid solvent called the mobile phase and then passing it through a system such as a chromatography column or a capillary tube upon which a material called the stationary phase is fixed. The different species present in the mixture have different affinities for and retention times upon the stationary phase, causing them to separate from the rest of the species in the moving fluid at characteristic rates. This phenomenon is exploited both to detect or measure the relative proportions of analytes present in a mixture, and to purify specific compounds.

Sources: en.wikipedia.org

Supporting material

Additionally, Saint George is regarded as a protector and healer in Druze tradition. The story of Saint George slaying the dragon is interpreted allegorically, representing the triumph of good over evil and the protection of the faithful from harm.

An ingredient is added to this list when it is excluded from use in a dietary supplement, does not appear to be an approved food additive or recognized as safe, and/or is subjected to the requirement for pre-market notification without having a satisfied requirement.

Obsidian hydration dating (OHD) is a geochemical method of determining age in either absolute or relative terms of an artifact made of obsidian. Obsidian is a volcanic glass that was used by prehistoric people as a raw material in the manufacture of stone tools such as projectile points, knives, or other cutting tools through knapping, or breaking off pieces in a controlled manner, such as pressure flaking. Obsidian obeys the property of mineral hydration and absorbs water, when exposed to air at a well-defined rate. When an unworked nodule of obsidian is initially fractured, there is typically less than 1% water present. Over time, water slowly diffuses into the artifact forming a narrow "band", "rim", or "rind" that can be seen and measured with many different techniques such as a high-power microscope with 40–80 power magnification, depth profiling with SIMS (secondary ion mass spectrometry), and IR-PAS (infra red photoacoustic spectroscopy). In order to use obsidian hydration for absolute dating, the conditions that the sample has been exposed to and its origin must be understood or compared to samples of a known age (e.g. as a result of radiocarbon dating of associated materials).

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha 1 made of?

It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.

Is thymosin alpha 1 a hormone?

It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.

Where is thymosin alpha 1 approved?

Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Network